@article {2418, title = {SCN9A and SCN10A Polymorphism and Therapeutic Effectiveness of Lidocaine Local Anesthetic Injection in Subjects with Diabetic Neuropathy Pain}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1259-1263}, type = {Original Article}, chapter = {1259}, abstract = {

Background: Diabetic neuropathy pain (DNP) is one of the complications experienced by more than half of the diabetic population. Treatment using lidocaine injection is one of the effective ways to manage pain in patients with DNP. Pain therapy using lidocaine locally targets the SCN9A and SCN10A genes, which encode the sodium receptors Nav1.7 and Nav1.8. The effect of lidocaine inhibits these sodium channels to reduce pain transmission. Purpose: This study aims to analyze the effect of polymorphism of genes encoding Nav1.7 and Nav1.8 on the effectiveness of lidocaine local injection therapy in patients with DNP. Methods: This study was an analytic observational study with a cross-sectional approach. A total of 63 people with DNP were genotyped for the SCN9A rs 6746030 gene and the SCN10A rs12632942 gene using Real-Time PCR/qPCR and DNA sequencing. Result: The results showed that 91.2\% and 70.6\% of the population who experienced decreased pain had the GA mutant allele in the SCN9A rs6746030 gene and the AG mutant allele in the SCN10A rs12632942 gene. The results showed a significant association of Nav1.7 and Nav1.8 gene polymorphisms with the effectiveness of lidocaine local anesthetic injection therapy in diabetic neuropathy pain patients (p \< 0.05). Conclusion: This study shows that there was an association between Nav1.7 and Nav1.8 gene polymorphisms and the effectiveness of lidocaine local anesthetic injection therapy in patients with DNP. Lidocaine injection therapy that targets the Nav1.7 and Nav1.8 sodium channels involving the SCN9A and SCN10A genes can be a therapeutic alternative for patients with DNP.

}, keywords = {Diabetes, Diabetic neuropathy pain, Nav1.7, Nav1.8, Polymorphism}, doi = {10.5530/pj.2024.16.204}, author = {I Made Subhawa Harsa and Andiani and Sulistiawati and Lilik Herawati and Hanik Badriyah Hidayati and Kuntaman} } @article {2056, title = {Correlation of Apo E Gene Polymorphism with Recurrent Acute Coronary Syndrome}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {June 2023}, pages = {450-453}, type = {Research Article}, chapter = {450}, abstract = {

Background: Recurrent cardiovascular disease (CVD) incidence puts patients at higher risk for mortality and morbidity. One of the CVD symptoms is acute coronary syndrome (ACS). Many genetic polymorphisms are CVD risk factors. This study{\textquoteright}s purpose was to investigate the correlation between recurrent ACS incidence and apolipoprotein E (ApoE) gene polymorphism. Method: Case-control design was used in this study. About 90 patients who visited the cardiology and internal medicine clinics at UNAIR Hospital in Surabaya, Indonesia, served as the study{\textquoteright}s subjects. There were 30 patients with recurrent ACS, 30 patients with a single ACS, and 30 patients with no history of cardiovascular disease. Afterward, using the polymerase chain reaction-restriction fragment length method, the ApoE gene polymorphism examination was carried out. The Tropical Disease Center UNAIR Laboratory conducted all laboratory testing. Results: In the recurrent ACS group, ApoE polymorphism genotype patterns were 5 subjects for ε2ε2 (16.67\%), 23 subjects for ε3ε3 (76.66\%), and 2 subjects for ε4ε4 (6.67\%). Meanwhile, in the single ACS group, ApoE polymorphism genotype patterns were 6 subjects for ε2ε2 (20\%), 22 subjects for ε3ε3 (73.4\%), 1 subject for ε4ε4 (3.33\%), and 1 subject for ε2ε3 (3.33\%). And, in the non- ACS group, ApoE polymorphism genotype patterns were4 subjects for ε2ε2 (13.34\%), 25 subjects for ε3ε3 (83.33\%), and1 subject for ε4ε4 (3.33\%). There was no correlation of ApoE gene polymorphism with recurrent ACS incidence by Chi-square analysis (p \> 0.05). Conclusion: ApoE gene polymorphism cannot significantly affect recurrent ACS incidence.

}, keywords = {Acute Coronary Syndrome, ApoE gene, PCR RFLP, Polymorphism, Public Health}, doi = {10.5530/pj.2023.15.100}, author = {Muhamad Robiul Fuadi and Jusak Nugraha and I Gde Rurus Suryawan and Hartono Kahar and Aryati and Gwenny Ichsan Prabowo and Budi Utomo and Reny I{\textquoteright}tishom} } @article {2059, title = {The Role of CYP3A4 and CYP2C8 Polymorphism on Amiodarone Responses: Review Article}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {June 2023}, pages = {467-470}, type = {Review Article}, chapter = {467}, abstract = {

Introduction: Amiodarone is one of drug with narrow therapeutics index. This medicine was metabolized by CYP3A4 and CYP2C8. The changes in the activity of this enzymes by CYP3A4 and CYP2C8 polymorphism will affect the effect. The study aimed to determine the impact of CYP3A4 and CYP2C8 polymorphism on amiodarone responses. Method: the study is review article with search article in PubMed with keywords: {\textquoteleft}amiodarone{\textquoteright} and {\textquoteleft}polymorphism of CYP3A4{\textquoteright} and {\textquoteleft}polymorphism of CYP2C8{\textquoteright}. Results: We collect 46 references to determine of impact polymorphism of CYP3A4 and CYP2C8 on amiodarone responses. Conclusion: Individual with CYP3A4*22 (rs35599367, 15389C\>T); CYP2C8*2 (A805T), CYP2C8*3 (G416A, A1196G), and CYP2C8*4 (C792G) and CYP2C8*4 polymorphism have lower activity of CYP3A4 and CYP2C8 enzymes and potentially cause adverse effect.

}, keywords = {Amiodarone responses., CYP2C8, CYP3A4, Polymorphism}, doi = {10.5530/pj.2023.15.103}, author = {Em Sutrisna} }